Kraig Biocraft Laboratories Rings in the New Year with the Most Ambitious Genetic Engineering Program in its History
Rhea-AI Summary
Kraig Biocraft Laboratories (OTCQB: KBLB) announced on January 20, 2026 that it has completed construction of its most advanced spider silk gene constructs and has begun active execution of a large-scale silkworm gene-engineering program. The initiative aims to substantially increase fiber strength and elasticity, expand production scalability, and advance commercial-scale recombinant spider silk manufacturing.
The company describes the program as its most ambitious genetic engineering effort to date and says it builds on years of proprietary research.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, KBLB declined 0.35%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
ANN ARBOR, Mich., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced that it is entering the new year with the implementation of the most ambitious and advanced genetic engineering initiative ever undertaken by the Company. The focus of this project is to dramatically increase strength and elasticity beyond anything ever seen in the area of recombinant spider silk.
The Company reported that its research and development team has successfully completed the construction phase of the most advanced spider silk gene constructs in Kraig’s history. With this milestone achieved, Kraig Labs has now begun the active execution phase of what represents the next evolution in silkworm gene engineering and recombinant spider silk production.
This initiative, now well underway, represents the largest and most complex silkworm gene-engineering project ever undertaken globally. The program builds upon years of proprietary research and production experience and is designed to further expand the performance, scalability, and commercial potential of the Company’s spider silk technologies.
"This project represents a defining moment for our technology platform," said Kim Thompson, Founder and CEO of Kraig Labs. "Our team has completed the most sophisticated spider silk gene constructs we have ever developed, and we are now advancing into the next phase, creating new materials that we believe will significantly expand the boundaries of what is possible in spider silk production. I believe this is the most ambitious application of genetic engineering to material science in world history and that this work will eclipse anything else being done in biomimicry or applications of molecular biology to material science."
The new genetic engineering program is intended to drive continued innovation across the Company's production pipeline, supporting enhanced fiber performance and future product diversification. Kraig Labs expects this effort to further strengthen its leadership position as it advances toward sustained commercial-scale spider silk manufacturing.
"This initiative reflects the depth of our expertise and our long-term commitment to innovation," Thompson added. "As we continue to advance commercialization of our current product offerings, we are simultaneously investing in the technologies that will define the next generation of spider silk."
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
FAQ
What did Kraig Biocraft Laboratories (KBLB) announce on January 20, 2026?
What are the goals of KBLB's new genetic engineering program?
Has Kraig Labs started producing the new spider silk at commercial scale?
Who commented on the new KBLB program and what did they say?
Does the announcement describe any completed sales, contracts, or regulatory approvals for KBLB's new silk?
Where can investors find updates about Kraig Biocraft Laboratories (KBLB)?
